# Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

> **NCT05416307** · PHASE2,PHASE3 · RECRUITING · sponsor: **Electra Therapeutics Inc.** · enrollment: 156 (estimated)

## Conditions studied

- Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

## Interventions

- **DRUG:** ELA026

## Key facts

- **NCT ID:** NCT05416307
- **Lead sponsor:** Electra Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-19
- **Primary completion:** 2027-06
- **Final completion:** 2029-06
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05416307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05416307, "Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05416307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*